A review-based and mechanistic set of reports highlights why immune responses often fail and how researchers are trying to redesign trials around tumor microenvironment differences. One review argues that opposing microenvironments help explain why regulatory T cell therapies have produced inconsistent outcomes across cancer and autoimmunity, proposing a biomarker-guided redesign approach. Another analysis discusses how cancer stem cell plasticity drives immune evasion and therapy resistance, pointing to combination strategies as a route to improve immunotherapy outcomes. Separately, a review of disrupted T-cell responses describes multiple points of immune breakdown and evaluates how existing immunotherapies attempt to restore anti-tumor activity—while acknowledging that most patients still do not achieve durable responses. Collectively, the pieces signal that the field is shifting from single-agent immune correction toward microenvironment- and state-aware intervention design.